Glaucoma
Cannabis reduces IOP short-term but duration is too brief for clinical utility
Cannabis reduces intraocular pressure (IOP) for 3–4 hours, but glaucoma requires 24-hour IOP control. The frequency of dosing required to maintain IOP reduction would produce significant systemic side effects. Not recommended as a primary glaucoma treatment.
At a Glance
Overview
Glaucoma is the leading cause of irreversible blindness worldwide, affecting approximately 3 million Americans. The primary modifiable risk factor is elevated intraocular pressure (IOP), and all approved glaucoma treatments work by reducing IOP.
Cannabis has been known to reduce IOP since the 1970s. Multiple studies have confirmed that smoked, oral, and intravenous THC reduces IOP by 25–30% — comparable to many approved glaucoma medications. This finding generated significant interest in cannabis as a glaucoma treatment.
However, the critical limitation is duration: THC's IOP-reducing effect lasts only 3–4 hours. Effective glaucoma management requires 24-hour IOP control. To maintain continuous IOP reduction with cannabis, a patient would need to dose 6–8 times daily — producing continuous psychoactive effects, tolerance, and significant systemic side effects (tachycardia, hypotension, cognitive impairment).
A 2006 American Academy of Ophthalmology position statement concluded that cannabis is not recommended for glaucoma treatment due to the short duration of action, systemic side effects, and the availability of more effective, better-tolerated alternatives (prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors).
CBG has shown IOP-reducing effects in animal models through α2-adrenoceptor agonism — a mechanism similar to brimonidine, an approved glaucoma medication. This is a more promising avenue for cannabinoid-based glaucoma therapy than THC, but human data are lacking.
Symptoms
- Elevated intraocular pressure
- Progressive peripheral vision loss
- Optic nerve damage
- Tunnel vision (advanced)
- Halos around lights (acute angle-closure)
- Eye pain (acute angle-closure)
- Often asymptomatic until advanced (open-angle)
How Cannabis Helps
THC reduces IOP by 25–30% through CB1 receptor-mediated reduction in aqueous humor production and increased outflow. CBG may reduce IOP through α2-adrenoceptor agonism. However, the 3–4 hour duration of action makes continuous IOP control impractical.
Treatment Options
Graded by quality of evidence. Grade A = strong (RCTs/FDA approval); B = moderate; C = preliminary.
THC (inhaled or oral)
Smoked/vaporized or oral
Reduces IOP 25–30% for 3–4 hours. Insufficient duration for clinical utility. Not recommended.
Would require 6–8 doses/day for continuous effect — impractical and harmful
CBG
Oral tincture
Animal model IOP reduction via α2-adrenoceptor agonism. No human trials. More promising mechanism than THC.
Research stage only — not a clinical recommendation
Key Studies
Primary literature supporting the evidence grade for this indication.
Marihuana smoking and intraocular pressure
Grade CJAMA, 1971
First study demonstrating cannabis reduces IOP. Established the pharmacological basis.
Cannabinoids in the treatment of glaucoma
Grade CSurvey of Ophthalmology, 2009
Review: IOP reduction confirmed but duration too brief for clinical utility. Not recommended.
CBG reduces intraocular pressure in animal model
Grade CExperimental Eye Research, 1984
CBG reduced IOP in cats via α2-adrenoceptor mechanism. Preclinical only.
Side Effects to Watch
- Tachycardia (may worsen glaucoma by increasing blood pressure)
- Hypotension (may reduce ocular perfusion pressure — potentially harmful)
- Cognitive impairment with frequent dosing
- Tolerance to IOP-reducing effects
Who Should Avoid
- All glaucoma patients as primary treatment
- Patients with cardiovascular disease
- Elderly patients
Dosing Guidance
Cannabis is NOT recommended for glaucoma management. Patients should use approved glaucoma medications (prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors, alpha-agonists) under ophthalmologist supervision.
Dosing information is for educational purposes only. Consult a licensed healthcare provider for personalized guidance.
Clinician Note
Counsel patients that despite cannabis reducing IOP, it is not an appropriate glaucoma treatment due to the short duration of action and systemic side effects. The hypotensive effect of cannabis may actually reduce ocular perfusion pressure, potentially worsening optic nerve damage. Refer to ophthalmology for appropriate treatment.
Related Conditions
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Cannabis remains a Schedule I controlled substance federally in the U.S. Always consult a qualified healthcare provider before making any medical decisions. Individual responses to cannabinoids vary significantly.